Role of apoptosis in adverse ventricular remodeling

Antonio Abbate1, Jagat Narula

  • 1VCU Pauley Heart Center, Virginia Commonwealth University, VCU Medical Center, 1200 East Broad Street, Richmond, VA 23298, USA. abbatea@yahoo.com

Heart Failure Clinics
|November 24, 2011
PubMed

Insights

Apoptosis, or programmed cell death, drives heart disease progression. Inhibiting this process may protect the heart from damage after a heart attack, potentially halting heart failure.

Area of Science:

  • Cardiology
  • Cell Biology
  • Pathology

Background:

  • Apoptosis plays a critical role in the development and progression of heart disease.
  • Stage B heart failure involves myocardial remodeling, making the heart muscle susceptible to programmed cell death.
  • Understanding apoptosis is crucial for managing heart conditions.

Purpose of the Study:

  • To review the role of apoptosis in the evolution of symptomatic heart failure.
  • To examine the impact of apoptosis on adverse myocardial remodeling post-acute myocardial infarction.

Main Methods:

  • Literature review focusing on apoptosis in heart failure.
  • Analysis of studies investigating programmed cell death in myocardial infarction.

Main Results:

  • Apoptosis is a key factor in heart disease progression.
  • Remodeled myocardium in Stage B heart failure is particularly vulnerable to apoptosis.
  • Inhibiting apoptotic stimuli or the cascade may preserve myocardial tissue.

Conclusions:

  • Targeting apoptosis offers a potential therapeutic strategy for heart failure.
  • Halting the apoptotic cascade could prevent adverse remodeling and disease progression.
  • Further research into apoptosis inhibition is warranted for cardiovascular disease management.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...